Manipal Health lists at 11% premium after ₹9,275 crore IPO
Bengaluru-based hospital chain Manipal Health Enterprises debuted at ₹655 on the BSE and ₹652 on the NSE, versus an IPO price of ₹590. The ₹9,275 crore issue was subscribed 4.92 times, led by 8.25-times QIB demand.
What happened
Bengaluru-based hospital chain Manipal Health Enterprises listed at Rs 655 on BSE and Rs 652 on NSE, about 11% above its Rs 590 IPO price. The Rs 9,275 crore
Key facts
- BSE listing price: Rs 655
- NSE listing price: Rs 652
- Issue price: Rs 590
- BSE listing premium: 11.02%
- NSE listing premium: 10.51%
- Profit per lot: Rs 1,625
- IPO price band: Rs 560-590 per share
- Lot size: 25 shares
- Total IPO size: Rs 9,275 crore
- Fresh issue: Rs 8,000 crore
- Offer for sale: Rs 1,275 crore
- Overall subscription: 4.92 times
- Applications: nearly 3.60 lakh
- QIB subscription: 8.25 times
- Non-institutional subscription: 1.02 times
- Employee subscription: 2.19 times
- Retail subscription: 93%
Why this matters
A successful ₹9,275 crore IPO gives Manipal Health stronger capital-markets credibility and potential flexibility to pursue expansion, technology investment, or strategic acquisitions.
What to watch
- First two quarterly results after listing, especially occupancy, ARPOB, EBITDA margin and net debt.
- Post-listing price stability and institutional ownership changes after the initial trading period.
- Announcements of hospital acquisitions, new-bed projects or specialty-care expansion.
- Comparable valuation moves in listed hospital, diagnostics and health-insurance companies.
- Changes in insurer reimbursement rates, government health-scheme pricing or healthcare affordability regulation.
- Use public-market visibility to accelerate organic bed-capacity additions and evaluate bolt-on hospital acquisitions.
- Prioritize investor communication on occupancy, margin trajectory, capex returns and leverage after listing.
- Competitors may revisit IPO, private-equity fundraising or asset-sale plans while sector valuations are supportive.
- Insurers and corporate-health buyers may seek tougher reimbursement negotiations if large hospital chains gain greater scale and bargaining power.